Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Targeting Abdominal Perfusion Pressure in Septic Shock (MAP-APP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03582046
Recruitment Status : Terminated (Lack of Enrollment)
First Posted : July 10, 2018
Last Update Posted : January 13, 2021
Sponsor:
Collaborators:
Emory University
University of Arkansas
Central Arkansas Veterans Healthcare System
Information provided by (Responsible Party):
Potrero Medical

Brief Summary:
A randomized control trial among patients with septic shock, studying the incidence, progression and recovery of AKI.

Condition or disease Intervention/treatment Phase
Acute Kidney Injury Septic Shock Resuscitations Device: Abdominal Perfusion Pressure (APP) Device: Mean Arterial Pressure (MAP) Not Applicable

Detailed Description:
Intra-abdominal pressure (IAP) has proven to be an important physiologic parameter in critically ill patients, and elevated IAP can lead to intra-abdominal hypertension (IAH). Literature suggests that IAH is common in patients with septic shock and that there is an association between the presence of IAH and acute kidney injury (AKI) in this group. Mean arterial pressure (MAP) and IAP together help determine the abdominal perfusion pressure (APP) of organs and tissues within the abdominal cavity. Current clinical guidelines for septic shock encourage targeting MAP of 65-70 mmHg with the use of vasopressors after volume resuscitation. However, it remains unclear if hemodynamic support targeting APP: (a) reduces development of acute kidney injury (AKI), (b) decreases progression of AKI, or (c) improves renal recovery rate compared to standard care for severe septic shock patients. A novel Foley catheter and monitoring device, the Accuryn Monitoring System, is capable of detecting physiologic changes in temperature, urine output (UO) and intra-abdominal pressure (IAP). These data streams are captured continuously by a device that is minimally invasive and at a high frequency which, in combination with MAP, allow for a simple calculation of abdominal perfusion pressure (APP). The purpose of this study is to assess kidney function and recovery in septic shock patients and elevated IAP when targeting treatment to maintain APP ≥ 60 mmHg as compared to standard of care targeting MAP of 65-70 mmHg.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Targeting Abdominal Perfusion Pressure in Septic Shock (The MAP APP Study)
Actual Study Start Date : February 5, 2019
Actual Primary Completion Date : February 27, 2020
Actual Study Completion Date : June 20, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock

Arm Intervention/treatment
No Intervention: Monitoring Group
Patients that sustain intra-abdominal pressure of < 8 mmHg for 48 hours from sepsis diagnosis. Patients will be monitored and given sepsis standard of care.
Active Comparator: Mean Arterial Pressure (MAP) Group
Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
Device: Mean Arterial Pressure (MAP)
Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.

Experimental: Abdominal Perfusion Pressure (APP) Group
Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
Device: Abdominal Perfusion Pressure (APP)
Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
Other Name: Intra-Abdominal Pressure (IAP)




Primary Outcome Measures :
  1. Study kidney function by controlling MAP targets to maintain APP levels, in critically ill patients with septic shock and elevated IAP. [ Time Frame: 90 days ]
    To study kidney function and recovery in patients with septic shock and elevated IAP as measured by timed creatinine clearance on calendar days 1-7 when targeting treatment to maintain APP ≥ 60 mmHg with a variable MAP target as compared to standard of care with a fixed MAP target. Creatinine clearance on calendar day 7 post-intervention or on day of ICU discharge, whichever is earliest, is the primary endpoint. Post hospital stay, subjects will have 30 day and 90 day follow up to check subject health status.


Secondary Outcome Measures :
  1. Study AKI by controlling MAP targets to maintain APP levels, in patients with IAH treated with standard of care versus patients with septic shock without IAH. [ Time Frame: 90 days ]
    To study the incidence, progression and recovery of AKI as well as patient-centered outcomes among patients with IAH treated by APP target versus standard of care. To study renal injury and recovery and patient-centered outcomes among septic shock patients without IAH.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult (age ≥ 18)
  2. Septic shock - identified as early as possible as evidenced by:

    1. Clinical diagnosis of sepsis defined as documented or suspected infection with the use of antibiotic administration OR
    2. Meets qSOFA (Quick Sequential Organ Failure Assessment) Criteria per the Sepsis-3 definitions:

    i. Respiratory rate ≥ 22/min ii. Altered mentation iii. Systolic blood pressure ≤ 100 mmHg AND c. Shock dependent on vasopressor therapy following initial 12-hour Resuscitation Period refractory to further volume expansion as assessed by clinical treatment team; this may be supported by either: i. Lack of blood pressure response following fluid bolus or passive leg raise ii. Hemodynamic data as available (e.g. PPV [positive pressure ventilation], SVV [stroke volume variation], echo, PAOP [pulmonary artery occlusion pressure], right-heart catheterization, etc.)

  3. Indication for a urinary bladder catheter (or one currently in place)
  4. Indication for an arterial line (or one currently in place at any site)

FOR MONITORING PHASE OF STUDY (MONITORING GROUP)

  1. All of the above criteria for the Resuscitation and Observational Periods of the study
  2. Intra-abdominal pressure < 8 mmHg

FOR INTERVENTION PHASE OF STUDY (APP VS MAP GROUPS)

  1. All of the above criteria for the Resuscitation and Observational Periods of the study
  2. Intra-abdominal pressure ≥ 8 mmHg

Exclusion Criteria:

  1. Inability to receive a urinary bladder catheter
  2. Chronic suprapubic catheter in place
  3. Cirrhosis/end stage liver disease, including Child-Pugh class C
  4. Severe AKI [acute kidney injury] as defined by life-threatening electrolyte, acidemia, or other indication for imminent emergent dialysis needs within 12 hours of hospital admission
  5. Evidence of chronic renal failure stage 5 (including serum creatinine values consistent with CKD 5 [chronic kidney disease, stage 5] or dialysis dependence) in 12-months prior to enrollment
  6. Active gastrointestinal bleed likely causing/contributing to the hemodynamic instability
  7. Acute intra-abdominal trauma (including intraabdominal surgery within the prior 30 days)
  8. Acute pancreatitis with no established source of infection
  9. Treating physician deems aggressive care is unsuitable, or has decided to de-escalate care [Do Not Resuscitate (DNR) patients receiving standard care are still eligible]
  10. In the opinion of the treating attending physician the patient is unsuitable for the study for any legitimate reason including lack of equipoise, anticipated imminent significant deterioration, anticipated imminent recovery, incarceration, pre-existing medical or psychiatric condition that treating attending physician deems not appropriate for study, or interfering medications
  11. Known previous or concurrent enrollment in a treatment clinical trial that, in the opinion of the investigator, might interfere with the objectives/endpoints of this clinical trial
  12. Known contraindication to bladder pressure measurement
  13. Known pregnancy
  14. Suspected or known increased intracranial pressure requiring active neurosurgical consultation
  15. Cardiogenic shock requiring extracorporeal support
  16. Any requirement for chest compressions prior to enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03582046


Locations
Layout table for location information
United States, Arkansas
Central Arkansas Veterans Healthcare System
Little Rock, Arkansas, United States, 72205
University of Arkansas Medical Center
Little Rock, Arkansas, United States, 72205
United States, Georgia
Grady Memorial Hospital
Atlanta, Georgia, United States, 30303
Sponsors and Collaborators
Potrero Medical
Emory University
University of Arkansas
Central Arkansas Veterans Healthcare System
Investigators
Layout table for investigator information
Principal Investigator: Michael J Connor, MD Emory University School of Medicine, (404) 616-0184 michael.connor@emory.edu
Principal Investigator: Luis Juncos, MD CAVHS, Little Rock, AR 72205 (501) 257-1000 luis.juncos@va.gov
Principal Investigator: Nithin Karakala, MD University of Arkansas Medical Center, Little Rock, AR NKarakala@uams.edu
Layout table for additonal information
Responsible Party: Potrero Medical
ClinicalTrials.gov Identifier: NCT03582046    
Other Study ID Numbers: CRD-06-2615
First Posted: July 10, 2018    Key Record Dates
Last Update Posted: January 13, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Shock, Septic
Acute Kidney Injury
Shock
Pathologic Processes
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation